NEW YORK (GenomeWeb News) – Definiens and Cernostics today announced that they will collaborate on the development of multiplex molecular diagnostics tests for a variety of cancers.
Danville, Pa.-based Cernostics will use Definiens' Tissue Studio digital pathology technology to develop the tests. The Definiens technology enables pathologists to analyze cancers on the cellular and sub-cellular level, the firms said.
"The collaboration with Definiens will enable Cernostics to accelerate development of its pipeline of systems biology-based diagnostic, prognostic and predictive tests," Cernostics CEO Michael Hoerres said in a statement.
Terms of the alliance were not disclosed.
Last year, Cernostics teamed up with Geisinger Health Systems to develop diagnostics for detecting cellular and molecular differences in patient tissue samples.